If you haven’t had time to catch-up on all the methods papers published in the last couple of months, here’s our take on the most important covering all aspects of HTA.
Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach.
Hawkins N, Richardson G, Sutton AJ, Cooper NJ, Griffiths C, Rogers A, Bower P.
Health Econ. 2012 Jun;21(6):742-56. doi: 10.1002/hec.1741. Epub 2011 Jul 28.
The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies.
Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D.
Int J Technol Assess Health Care. 2012 Apr;28(2):138-44.
Bayesian meta-analysis on medical devices: application to implantable cardioverter defibrillators.
Youn JH, Lord J, Hemming K, Girling A, Buxton M.
Int J Technol Assess Health Care. 2012 Apr;28(2):115-24.
Accounting for biases when linking empirical studies and simulation models.
Goldhaber-Fiebert JD.
Med Decis Making. 2012 May-Jun;32(3):397-9.
Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS, Ray S, Ganguli A, Cella D.
Value Health. 2012 Mar-Apr;15(2):305-11. Epub 2012 Feb 2.
Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis: An Application of Bayesian Methods for Evidence Synthesis in a Markov Model.
Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.
Pharmacoeconomics. 2012 Jul 1;30(7):575-93.
